EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis

Nabila Ibnou Zekri Lassout iD, Vishal Goyal iD, Edrich Krantz, Francois Simon iD, Anouk Neven iD, Johanna Eriksson iD, Amaria Saayman, Vijay Satam, Carol Ruffell iD, Sarika Victor, Marylore Chenel, Aljosa Celebic iD und 6 weitere

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13908 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Nabila Ibnou Zekri Lassout und 17 weiteren Autor:innen. Beteiligte Einrichtung: Drugs for Neglected Diseases Initiative, Geneva, Switzerland. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, Flucytosine, Biological Availability, Cross-Over Studies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cryptococcal meningoencephalitis (CM) is an opportunistic fungal infection and a major cause of death among people living with human immunodeficiency virus in sub‐Saharan Africa. 5‐flucytosine (5‐FC) is a unique, brain‐permeable antifungal agent used to reduce mortality from CM and to prevent disease in individuals carrying cryptococcal antigen. 5‐FC has a short plasma half‐life, requiring 6‐hourly oral dosing with an immediate‐release (IR) formulation, a significant challenge in hospital and outpatient settings, risking a lack of compliance. We recently reported the relative bioavailability in fasting conditions of a sustained release (SR) oral pellet formulation of 5‐FC. In this phase I study, we assessed the safety and pharmacokinetic profiles of the new 5‐FC SR formulation in a single dose (2 × 3000 mg), relative to 5‐FC IR tablets (Ancotil®; 1500 mg b.i.d.) in healthy participants in fed conditions. This randomized, two‐period crossover study was conducted in South Africa to confirm the dose of the identified 5‐FC SR formulation for a twice‐daily 5‐FC regimen in patients. Thirty‐six healthy participants were included. All treatments were well tolerated and no serious adverse event was reported. C max and AUC (0– t ) for the SR formulation (49.2 ± 10.49 μg/mL and 640.4 ± 126.4 h.μg/mL, respectively) were significantly higher than for the IR formulation (36.8 ± 7.61 μg/mL and 456.6 ± 72.8 h.μg/mL, respectively). A physiological based pharmacokinetic model (PBPK) predicted that under fasting conditions, 6000 mg SR pellets would show a good overlap with the IR product (3000 mg b.i.d), thus 6000 mg SR 5‐FC b.i.d. in fasting conditions is recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningitis, CryptococcalFlucytosineBiological AvailabilityCross-Over StudiesDelayed-Action PreparationsAntifungal AgentsHumansMaleAdultFemaleMiddle AgedYoung AdultAdministration, OralHealthy VolunteersAdolescentSouth AfricaArea Under Curve

Substanzen

FlucytosineDelayed-Action PreparationsAntifungal Agents

Autor:innen und Institutionen

  • Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
  • Drugs for Neglected Diseases Initiative, New York, New York, USA.
  • FARMOVS, Bloemfontein, South Africa.
  • Competence Center for Methodology and Statistics (CCMS), Luxembourg Institute of Health, Strassen, Luxembourg.
  • Pharmetheus, Uppsala, Sweden.
  • Drugs for Neglected Diseases initiative, New Delhi, India.

ORCID-Profile: Nabila Ibnou Zekri Lassout, Vishal Goyal, Francois Simon, Anouk Neven, Johanna Eriksson, Carol Ruffell, Aljosa Celebic, Henri Caplain, Jean-Yves Gillon, Isabela Ribeiro

Zitieren

APA

Ibnou Zekri Lassout, N., Goyal, V., Krantz, E., Simon, F., Neven, A., Eriksson, J., Saayman, A., Satam, V., Ruffell, C., Victor, S., Chenel, M., Celebic, A., Caplain, H., Gillon, J. Y., Deshmukh, A., Antarkar, A., Sjögren, E., & Ribeiro, I. (2024). Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis. Clinical and Translational Science. https://doi.org/10.1111/cts.13908

Vancouver

Ibnou Zekri Lassout N, Goyal V, Krantz E, Simon F, Neven A, Eriksson J, et al. Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis. Clinical and Translational Science. 2024. doi:10.1111/cts.13908

BibTeX
@article{IbnouZekriLassout2024,
  author = {Ibnou Zekri Lassout, Nabila and Goyal, Vishal and Krantz, Edrich and Simon, Francois and Neven, Anouk and Eriksson, Johanna and Saayman, Amaria and Satam, Vijay and Ruffell, Carol and Victor, Sarika and Chenel, Marylore and Celebic, Aljosa and Caplain, Henri and Gillon, Jean-Yves and Deshmukh, Abhijit and Antarkar, Amit and Sjögren, Eric and Ribeiro, Isabela},
  title = {Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13908}
}
Kostenlos starten →